PVI
GYRE icon

Pura Vida Investments’s Gyre Therapeutics GYRE Stock Holding History

Pura Vida Investments’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-47,574
Closed -$326K – 249
2021
Q4 		$326K Sell
47,574
-2,104
-4% -$36K 0.01% 220
2021
Q3 		$1.53M Buy
+49,678
New +$1.63M 0.05% 203
2018
Q1 		– Sell
-8,000
Closed -$818K – 78
2017
Q4 		$818K Buy
+8,000
New +$408K 0.34% 59

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Pura Vida Investments's GYRE Position: Q1 2022 in Review

Pura Vida Investments sold out of Gyre Therapeutics (GYRE) in Q1 2022, closing a stake of 47,574 shares — an estimated $326K sold.

Pura Vida Investments first reported a position in GYRE in Q4 2017 and held it in 3 quarters. The position peaked at $1.53M in Q3 2021. 43 funds tracked by Wall St. Rank hold GYRE as of Q1 2022.

  • Pura Vida Investments reported no remaining Gyre Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Pura Vida Investments sold 47,574 Gyre Therapeutics shares in Q1 2022, an estimated $326K.
  • Pura Vida Investments first reported a position in Gyre Therapeutics in Q4 2017 and held it in 3 quarters.
  • Pura Vida Investments's Gyre Therapeutics position peaked at $1.53M in Q3 2021.
  • 43 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2022.

Based on Pura Vida Investments's 13F filing for Q1 2022, filed 16 May 2022.